Regenerative Medicine at NYSCF
NYSCF is developing an autologous iPSC-derived retinal pigment epithelium cell product on a biodegradable scaffold for dry age-related macular degeneration. This program is on track to enter a Phase 1 clinical trial in 2025 and is available for partnership.
cGMP iPSC Lines Available for Purchase
NYSCF offers off-the-shelf cGMP iPSCs and matching research-grade iPSCs. Our first product will be available soon from a healthy male donor.
- Starting material: CD34+ blood
- Reprogramming method: Sendai virus
- Additional donor characteristics (blood type, HLA profile, etc.) available upon request
Contact us to learn more about this product and the ordering process.
cGMP iPSC Manufacturing Services
In addition to our readily available cell lines, we offer custom cGMP iPSC line generation services. Our clinical manufacturing team has developed proprietary reprogramming methodology and generated cGMP iPSC lines from multiple donors in our GMP and ISO-compliant cleanroom.
Contact us now to speak with our experts and book this service.
We also consider opportunities to co-develop cell therapies or to become your manufacturing partner for the preclinical through early clinical stages.